Wallace PM - Search Results

1

Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule.

Linsley PS, Wallace PM, Johnson J, Gibson MG, Greene JL, Ledbetter JA, Singh C, Tepper MA. Linsley PS, et al. Among authors: wallace pm. Science. 1992 Aug 7;257(5071):792-5. doi: 10.1126/science.1496399. Science. 1992. PMID: 1496399

2

CTLA4Ig treatment ameliorates the lethality of murine graft-versus-host disease across major histocompatibility complex barriers.

Wallace PM, Johnson JS, MacMaster JF, Kennedy KA, Gladstone P, Linsley PS. Wallace PM, et al. Transplantation. 1994 Sep 15;58(5):602-10. doi: 10.1097/00007890-199409150-00013. Transplantation. 1994. PMID: 8091487

3

Induction and reversal of long-lived specific unresponsiveness to a T-dependent antigen following CTLA4Ig treatment.

Wallace PM, Rodgers JN, Leytze GM, Johnson JS, Linsley PS. Wallace PM, et al. J Immunol. 1995 Jun 1;154(11):5885-95. J Immunol. 1995. PMID: 7751633

4

In vivo properties of oncostatin M.

Wallace PM, Macmaster JF, Rillema JR, Rouleau KA, Hanson MB, Burstein SA, Shoyab M. Wallace PM, et al. Ann N Y Acad Sci. 1995 Jul 21;762:42-54. doi: 10.1111/j.1749-6632.1995.tb32313.x. Ann N Y Acad Sci. 1995. PMID: 7545375 Review. No abstract available.

5

Application of monoclonal antibodies against cytosine deaminase for the in vivo clearance of a cytosine deaminase immunoconjugate.

Kerr DE, Garrigues US, Wallace PM, Hellström KE, Hellström I, Senter PD. Kerr DE, et al. Among authors: wallace pm. Bioconjug Chem. 1993 Sep-Oct;4(5):353-7. doi: 10.1021/bc00023a008. Bioconjug Chem. 1993. PMID: 8274519

6

Regulation of inflammatory responses by oncostatin M.

Wallace PM, MacMaster JF, Rouleau KA, Brown TJ, Loy JK, Donaldson KL, Wahl AF. Wallace PM, et al. J Immunol. 1999 May 1;162(9):5547-55. J Immunol. 1999. PMID: 10228036

7

Prodrugs of doxorubicin and melphalan and their activation by a monoclonal antibody-penicillin-G amidase conjugate.

Vrudhula VM, Senter PD, Fischer KJ, Wallace PM. Vrudhula VM, et al. Among authors: wallace pm. J Med Chem. 1993 Apr 2;36(7):919-23. doi: 10.1021/jm00059a018. J Med Chem. 1993. PMID: 8464046

8

In vitro and in vivo activities of a doxorubicin prodrug in combination with monoclonal antibody beta-lactamase conjugates.

Svensson HP, Vrudhula VM, Emswiler JE, MacMaster JF, Cosand WL, Senter PD, Wallace PM. Svensson HP, et al. Among authors: wallace pm. Cancer Res. 1995 Jun 1;55(11):2357-65. Cancer Res. 1995. PMID: 7757987

9

Activation of prodrugs by antibody-enzyme conjugates.

Senter PD, Wallace PM, Svensson HP, Kerr DE, Hellstrom I, Hellstrom KE. Senter PD, et al. Among authors: wallace pm. Adv Exp Med Biol. 1991;303:97-105. doi: 10.1007/978-1-4684-6000-1_12. Adv Exp Med Biol. 1991. PMID: 1805578 No abstract available.

10

Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates.

Wallace PM, Senter PD. Wallace PM, et al. Methods Find Exp Clin Pharmacol. 1994 Sep;16(7):505-12. Methods Find Exp Clin Pharmacol. 1994. PMID: 7885077 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

71 results

Search Page